Prostate cancer (PCa) affects millions of men globally. Due to advances in understanding
genomic landscapes and biological functions, the treatment of PCa continues to improve …

The NR superfamily comprises 48 transcription factors in humans that control a plethora of
gene network programs involved in a wide range of physiologic processes. This review will …

Prostate cancer is heterogeneous and patients would benefit from methods that stratify those
who are likely to respond to systemic therapy. Here, we employ single-cell assays for …

Androgen deprivation therapy for prostate cancer (PCa) benefits patients with early disease,
but becomes ineffective as PCa progresses to a castration-resistant state (CRPC). Initially …

Metastatic prostate cancer patients present in two ways—with already disseminated disease
at the time of presentation or with disease recurrence after definitive local therapy. Androgen …

Prostate cancer has a long disease history and a wide variety and uncertainty in individual
patients' clinical progress. In recent years, we have seen a revolutionary advance in both …

Aberrant androgen receptor (AR) signaling drives prostate cancer (PC), and it is a key
therapeutic target. Although initially effective, the generation of alternatively spliced AR …

Resistance to next-generation anti-androgen enzalutamide (ENZ) constitutes a major
challenge for the treatment of castration-resistant prostate cancer (CRPC). By performing …

Prostate cancer (PCa) is heterogeneous, harboring phenotypically diverse cancer cell types.
PCa cell heterogeneity is caused by genomic instability that leads to the clonal competition …

Binding of toxic ligands to DNA could result in undesirable biological processes, such as
carcinogenesis or mutagenesis. Binding mode of Abiraterone (ABR), a steroid drug and calf …